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4 According to the CDC, more than 70% of the bacteria now causing hospitalacquired infections are resistant to at least one of the drugs most commonly used to treat them. 5 It seems important to control these infections because they have been more costly and more deadly than those due to antibiotic-susceptible strains of the same species. 6 " 9 Nevertheless, despite decades of discussing the control of antibiotic-resistant nosocomial infections, there has been little evidence of control in most healthcare facilities in most countries. The first of these, by L'Heriteau et al., 10 reports the findings of a nationwide, prospective study designed to describe methods used for diagnosis and surveillance of nosocomial infections and multidrug-resistant organisms in French intensive care units (ICUs). They sought to survey all 573 French ICUs, but only 252 (44%) responded to the written survey. Follow-up telephone interviews of personnel in 143 (47%) of the initially nonresponding ICUs allowed them to increase the overall response rate to 69%. Despite the existence of clearly stated French national guidelines, 15 the authors found that there were "profound differences" in the way that ICUs had implemented the recommendations for surveying for various nosocomial infections. They concluded that great caution must be exercised when comparing data regarding ICU infections among French hospitals. Regarding surveillance for multidrug-resistant organisms, they found that 70% of the respondents performed active surveillance cultures to detect these organisms on admission, whereas 60% did so during the stay; 88% of the responding ICUs flagged carriers of multidrug-resistant organisms so that isolation could be maintained consistently. This indicates important variation among hospitals, and inconsistent use of an effective control measure could help to explain difficulties in controlling multidrug-resistant organisms (ie, approximately one-third of the time active surveillance cultures were not being performed to identify contagious patients).
A second national survey in this issue of Infection Control and Hospital Epidemiology was designed to examine the extent of implementation of strategies to control multidrug-resistant organisms in U.S. hospitals based on recommendations from a 1994 workshop co-sponsored by the National Foundation for Infectious Diseases and the CDC. 16 Ward et al. 11 surveyed hospitals for compliance with five goals to optimize antibiotic use and five goals to detect, report, and prevent spread of multidrug-resistant organisms. From approximately 7,000 U.S. hospitals, 108 hospitals (1.5%) were randomly selected to receive a survey (excluding Veterans' Affairs hospitals and small-to medium-sized teaching hospitals). The survey response rate was 60%. Approximately half of the responding hospitals were classified as large (> 200 beds) and an equal proportion of those remaining as small (50 to 99 beds) and medium (100 to 199 beds). Survey responses were recorded using a 5-point Likert scale. The mean response regarding each strategy was less than 4, indicating only moderate compliance. Nevertheless, they found no differences regarding bed size, teaching status, or geographic region, suggesting that hospitals of all sizes and types may have potential to successfully implement such goals. The authors concluded that hospitals need to do more to improve antimicrobial use and to detect, report, and control the spread of multidrug-resistant organisms. The use of active surveillance cultures to detect multidrug-resistant organisms to ensure appropriate isolation, a major focus of the French national study 10 and also of a recent Society for Healthcare Epidemiology of America (SHEA) guideline for preventing the transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus, 17 was not mentioned in this study of U.S. hospitals, perhaps because the National Foundation for Infectious Diseases-CDC workshop recommendations on which it was based did not comment on this approach.
Flach et al. 12 conducted a sophisticated study designed to assess U.S. hospitals' methods for identifying bacterial antimicrobial resistance, reporting it to clinicians, and monitoring its spread in a timely manner. Five variables were studied: (1) disseminating antibiograms to physicians at least annually, (2) notifying physicians of antimicrobial-resistant infections, (3) reporting susceptibility results within 24 hours, (4) using automated testing procedures, and (5) offering molecular typing. Eighty-five (78%) of 106 U.S. hospitals selected to receive the survey responded. The use of individual procedures ranged from 33% to 85%. The authors concluded that this represented great variability and that hospitals are not doing enough to monitor spread. Once again, active surveillance cultures were not mentioned despite the fact that recent studies have suggested that 85% of all hospitalized patients colonized with methicillin-resistant S. aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) go unrecognized and unisolated in the absence of active surveillance cultures 1819 and that patients with multidrug-resistant organisms cared for using standard precautions have been significantly more likely to transmit them than have those cared for using contact precautions. 2021 The article by Lee et al. 13 in this issue of Infection Control and Hospital Epidemiology examines the sensitivity and cost-effectiveness associated with three active surveillance culture strategies for identifying VRE-colonized patients. At the study onset, routine active surveillance cultures for VRE were being performed for patients in highrisk areas (ie, hematology-oncology unit, bone marrow and solid organ transplant unit, and surgical and medical ICUs). This strategy was referred to as CURRENT and was compared with two additional strategies: screening the CURRENT patients plus those with a history of renal disease (RENAL) and screening CURRENT patients plus those hospitalized in the previous 2 years (HOSP). For each of the surveillance strategies, the costs of screening and of hospitalization per admission were calculated and the survival rate was estimated.
In addition to their CURRENT strategy, 200 consecutive stool specimens submitted for Clostridium difficile testing were screened for VRE. Seventeen of the 81 specimens submitted from high-risk units were positive for VRE; 16 of these were also identified via CURRENT methods. The expanded testing identified 5 non-high-risk VRE colonizations. All 22 patients identified as colonized with VRE had been hospitalized within the prior 2 years. Only 3 of the 5 non-high-risk patients had a history of renal impairment. VRE cultures of diarrheal stool specimens submitted for C. difficile screening would have resulted in missing 71% of the patients colonized with VRE. The HOSP strategy would involve screening the greatest number of patients (all those with a hospital admission in the prior 2 years), resulting in slightly higher screening costs; however, this strategy resulted in greater recognition of currently undetected colonization and was associated with lower overall costs due to improved control of VRE and optimal estimated survival rates. For these reasons, the authors advocated expanding VRE surveillance programs to include patients hospitalized in the prior 2 years.
As mentioned above, Ward et al. concluded that efforts to control the inappropriate use of antimicrobials were insufficient in many U.S. hospitals. In this issue of Infection Control and Hospital Epidemiology, Bolon et al. 14 report frequent inappropriate use of vancomycin in the pediatric wards of a single hospital almost a decade after the CDC made recommendations regarding how vancomycin use should be controlled. 22 Fortunately, a metaanalysis from the same university found that vancomycin use was not a particularly important risk factor for VRE acquisition, 23 but this does not mean that it cannot play some role in potentiating the survival and spread of VRE. Inappropriate use is also associated with excess costs and the risk of unnecessary side effects for patients. This study serves to reinforce the conclusion of Ward et al. that despite decades of trying, we have not yet become very good at optimizing antimicrobial use.
As stated earlier, there has been widespread failure to control antibiotic-resistant nosocomial infections due to pathogens such as MRSA and VRE. The five studies discussed in this editorial suggest that a major reason for this failure of control has been the frequent failure of hospitals to use effective measures. What should be done to rectify this situation? Hospitals should begin following an evidence-based approach. The combination of strategies advocated by the SHEA guideline on control of MRSA and VRE, 17 emphasizing identification and containment of spread, is the most effective method documented to date for controlling multidrug-resistant organisms. Notably, it has been recommended by the CDC for control of "important" pathogens ranging from severe acute respiratory syndrome to vancomycin-resistant S. aureus. 24 - 25 The recent, draft Healthcare Infection Control Practices Advisory Committee guideline proposed intensifying prevention interventions for multidrug-resistant organisms whenever there is evidence of their continuing transmission within a facility. 26 As the overall prevalence of multidrug-resistant organisms continues to increase nationally, 24 one might 
